Retatrutide vs Aleniglipron: Injectable Triple Agonist vs Oral GLP-1 Phase 2b Data
TL;DR: Oral aleniglipron hit 16.2% weight loss in Phase 2b (Nature Med, 5 Jun 2026); retatrutide's Phase 3 already reports 28.3%.
What Is Aleniglipron and How Does It Differ From Retatrutide?
Aleniglipron is an investigational compound from Structure Therapeutics (NASDAQ: GPCR), and it differs from retatrutide in a fundamental way: it is not a peptide at all. Aleniglipron is an orally administered small-molecule GLP-1 receptor agonist — a once-daily pill, not an injection. Retatrutide, by contrast, is a subcutaneously injected peptide that acts on three receptors simultaneously (GLP-1, GIP and glucagon), the mechanism behind its Phase 3 TRIUMPH programme results.[4]
The route of administration is the headline difference for research purposes. Peptide GLP-1/GIP/glucagon agonists such as retatrutide, tirzepatide and semaglutide require cold-chain storage and subcutaneous injection because peptide bonds are degraded by digestive enzymes if swallowed. A stable, orally bioavailable small molecule that activates the same GLP-1 receptor sidesteps that constraint entirely, which is why aleniglipron's Phase 2b data drew attention from researchers tracking the broader incretin field even though its reported effect sizes remain well behind retatrutide's.
What Did Aleniglipron's Phase 2b ACCESS Trial Report?
Design: 230 adults with overweight or obesity (mean BMI 39.5 kg/m², 54% female) were randomised to once-daily oral aleniglipron, escalated every four weeks to a target dose of 45mg, 90mg or 120mg, versus matched placebo, over 36 weeks. Result at 36 weeks (primary endpoint): placebo-adjusted least-squares mean body-weight change of −8.2%, −9.8% and −11.3% for the 45mg, 90mg and 120mg arms respectively (p<0.0001 for all doses vs placebo). Open-label extension: an interim analysis after a median further 20 weeks of follow-up reported weight loss of 13.3%, 16.2% and 15.3% in participants originally randomised to the 45mg, 90mg and 120mg arms. Secondary endpoints: systolic and diastolic blood pressure, hsCRP, waist circumference and HbA1c all improved alongside weight loss. Tolerability: the discontinuation rate was 10.4%, with gastrointestinal adverse events (nausea, vomiting, diarrhoea) typical of the GLP-1 receptor agonist class as the main driver.[1][2]
Source: Nature Medicine, 2026; DOI: 10.1038/s41591-026-04476-6
Structure Therapeutics announced the publication via press release on 5 June 2026, framing the open-label extension figures as evidence that weight loss on aleniglipron had not plateaued by week 36 and continued to accrue with longer exposure — a pattern also reported in retatrutide's own dose-escalation trials.[2]
How Do Aleniglipron and Retatrutide's Trial Data Compare Side by Side?
| Compound & dose | Trial (phase) | n | Duration | Reported result |
|---|---|---|---|---|
| Aleniglipron 120mg | ACCESS obesity (Phase 2b) | 230 | 36 wks | −11.3% weight (placebo-adj.) |
| Aleniglipron 90mg | ACCESS open-label extension | 230 | 36 wks + 20 wks | −16.2% weight (interim) |
| Retatrutide 12mg | TRIUMPH-1 obesity (Phase 3) | 2,339 | 80 wks | −28.3% weight (up to −30.3% at 104 wks) |
| Retatrutide (T2D arm) | TRANSCEND-T2D-1 (Phase 3) | 537 | 40 wks | A1C −2.0pp; weight −16.8% |
Figures are as reported in each publication, at different trial phases, populations, doses and durations. This table is for contextual research reference only and is not a head-to-head clinical comparison.
Read plainly, retatrutide's Phase 3 numbers remain roughly double aleniglipron's furthest published result. But as with other early-stage pipeline compounds covered in our comparison of retatrutide against Novo Nordisk's zenagamtide, the gap is partly a function of trial phase and route of administration rather than a settled read on relative efficacy. Aleniglipron's Phase 2b population is nine-fold smaller than TRIUMPH-1's, its primary endpoint window is under half as long, and oral small molecules in this class have historically shown smaller effect sizes than injectable peptides at equivalent trial phases — a pattern also seen when comparing injectable and oral formulations of semaglutide.
Why Does an Oral Small-Molecule GLP-1 Agonist Matter for Incretin Research?
A formulation-first differentiator
Aleniglipron's research interest sits mainly in its delivery mechanism, not (yet) its efficacy. A tablet with no cold-chain requirement and no injection removes a major manufacturing and logistics constraint that applies to every peptide GLP-1/GIP/glucagon agonist, including retatrutide, tirzepatide and semaglutide's injectable form.
Single-receptor vs multi-receptor agonism
Aleniglipron activates only the GLP-1 receptor. Retatrutide's triple-receptor mechanism (GLP-1, GIP and glucagon) is the leading hypothesis for why its Phase 3 weight-loss figures substantially exceed those reported for single-receptor GLP-1 agonists across the published literature, oral or injectable.
Trial-phase gap is the key caveat
Aleniglipron is roughly two full trial phases behind retatrutide's most advanced obesity data. Its Phase 2b dataset, even including the open-label extension, is an early signal rather than confirmatory evidence, and a planned Phase 3 programme could shift the reported effect size materially in either direction.
What's Next in Aleniglipron's Development Timeline?
Structure Therapeutics has said a Phase 3 programme for aleniglipron is planned to begin in the third quarter of 2026, using a lower 2.5mg starting dose intended to improve early gastrointestinal tolerability during titration, before escalating toward the doses tested in ACCESS.[3] As of this writing, no Phase 3 results have been reported for aleniglipron. That timeline runs in parallel with, and is entirely separate from, retatrutide's own regulatory track: Lilly has said it will submit a Biologics License Application for retatrutide in Q1 2027, following the completed TRIUMPH-1 and newly reported TRIUMPH-2/TRIUMPH-3 Phase 3 results.
What Should UK Researchers Take From This?
Aleniglipron is an unapproved, patent-protected Structure Therapeutics investigational compound confined to registered clinical trials. It is not available for purchase, compounding, or research use from any lawful source, and Velox Peptides does not supply it or any small-molecule GLP-1 agonist. Its published data is presented here purely as third-party scientific context for researchers tracking the wider incretin-receptor field that retatrutide research sits within.
That does not change retatrutide's own regulatory position. It remains an unlicensed investigational medicine, with a Q1 2027 BLA submission targeted in the US following its Phase 3 TRIUMPH programme, and no confirmed MHRA timeline. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with batch-specific certificates of analysis, and makes no therapeutic or weight-loss claims for it.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. Aleniglipron is not a Velox Peptides product and is not available for sale. See our Research Use Policy and MHRA Statement.
References
- Structure Therapeutics. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04476-6
- Structure Therapeutics. Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity. Press release, 5 June 2026. globenewswire.com
- Technology Networks. Oral GLP-1 Drug Shows Promising Weight Loss Results in Phase 2 Trial. June 2026. technologynetworks.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, 21 May 2026. investor.lilly.com
- Velox Peptides. Retatrutide TRIUMPH-2 & TRIUMPH-3 Report: Diabetes and Cardiovascular Phase 3 Results. 23 July 2026. veloxpeps.com/guides
Frequently Asked Questions
What is aleniglipron?
Aleniglipron is Structure Therapeutics' investigational, orally administered small-molecule GLP-1 receptor agonist. Unlike retatrutide, which is an injectable peptide acting on three receptors (GLP-1, GIP and glucagon), aleniglipron is a once-daily pill acting on a single receptor, the GLP-1 receptor. It is not approved for human use in any jurisdiction.
What did aleniglipron's Phase 2b ACCESS trial show?
Published in Nature Medicine on 5 June 2026, the ACCESS Phase 2b trial randomised 230 adults with overweight or obesity to once-daily oral aleniglipron (45mg, 90mg or 120mg) or placebo. At the 36-week primary endpoint, placebo-adjusted weight loss was 8.2%, 9.8% and 11.3% respectively (all doses p<0.0001 vs placebo). An open-label extension with a median 20 further weeks of follow-up reported weight loss of up to 16.2% on the 90mg arm.
How does aleniglipron compare with retatrutide's trial data?
Retatrutide's Phase 3 TRIUMPH-1 trial reported 28.3% weight loss at 80 weeks (up to 30.3% at a 104-week extension) in 2,339 participants. Aleniglipron's most advanced published data is still Phase 2b, in 230 participants, reporting up to 16.2% weight loss including open-label extension follow-up. The two cannot be compared head-to-head: different trial phases, different populations, different durations, and different mechanisms (single-receptor oral small molecule vs triple-receptor injectable peptide).
Is aleniglipron an oral peptide?
No. Aleniglipron is a small-molecule drug, not a peptide. It is taken as an oral tablet with no injection or cold-chain requirement, which distinguishes its formulation approach from retatrutide and other GLP-1/GIP/glucagon peptide agonists that require subcutaneous injection.
Is aleniglipron available as a research reagent?
No. Aleniglipron is an unapproved, patent-protected Structure Therapeutics investigational compound confined to registered clinical trials. It is not available for purchase, compounding, or research use from any lawful source, and Velox Peptides does not supply it.
Is retatrutide available as a research reagent?
Yes. Velox Peptides supplies retatrutide as an HPLC-verified (≥99% purity) lyophilised research reagent for in vitro laboratory research only. It is not licensed as a medicine, is not evaluated by the MHRA or FDA, and is not intended for human or veterinary use.